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Atherosclerosis represents an important chronic inﬂammatory process associated with several pathophysiological reactions in
the vascular wall. The arachidonic acid, released by phospholipase A2, is an important substrate for the production of a group
of lipid mediators known as leukotrienes, which induce proinﬂammatory signaling through the activation of speciﬁc BLT and
CysLT receptors. The interaction of these substances in the vascular wall determines important morphological alterations like the
early lipid retention and the accumulation of foam cells, the development of intimal hyperplasia, and advanced atherosclerotic
lesions, and it plays an important role in the rupture of atherosclerotic plaque. Many studies regarding myocardial ischemia
and reperfusion show that leukotriene signaling may be involved in the development of ischemic injury. For these, reasons both
leukotrienesynthesisinhibitorsandleukotrienereceptorantagonistshavebeensuggestedforinducingbeneﬁcialeﬀectsatdiﬀerent
stages of the atherosclerosis process and may represent a new therapeutic target in the treatment of atherosclerotic vessel diseases,
in particular in acute coronary syndrome.
Copyright © 2009 Graziano Riccioni et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cysteinyl leukotrienes (Cys-LTs) are potent inﬂammatory
lipid mediators derived from the 5-lypoxygenase (5-LO)
pathway of arachidonic acid (AA) metabolism [1], initially
identiﬁed to have important eﬀects on pathogenetic aspects
of allergic rhinitis and bronchial asthma and approved in the
late 1990s for the relief of perennial and seasonal allergic
rhinitis symptoms, and the treatment of mild persistent
bronchial asthma [2–5].
Recently many studies revealed the presence of Cys-LTs
in atherosclerotic lesions playing a key role as signaling
molecules in atherosclerosis [6, 7], abdominal aneurysms
[8, 9], intimal hyperplasia [10], and with possible eﬀects on
tumorigenesis [11, 12]. For these reasons, the leukotriene
pathway may represent an alternative therapeutic target in
the treatment of atherosclerotic vessel diseases [6, 13, 14].
2.Biochemistry of Endothelium
Vascular endothelium is an active endocrine, paracrine,
and autocrine organ, indispensable for the maintenance of
vascular homeostasis [15]. When it is altered by various
stimuli, it may cause localized alterations or “endothelial
dysfunction” having antihemostatic properties, regulating
vascular tone, determining a heightened leukocyte adhesion,
and increase production of cytokines and growth factors
[16]. The term “endothelial activation” designates a subset
of endothelial dysfunction whereby some changes produced
by various stimuli elicit new functional and molecular
properties. The endothelium activation contributes to the
regulationofvasculartone,haemostasis,andbloodleukocyte
recruitment and determines the releasing of vasodilators like
nitric oxide [17] and prostacyclin [18], and vasoconstrictors
such as endothelin [19] and platelets activating factor [20].2 Mediators of Inﬂammation
3. Biochemistry of Leukotrienes:
Mediators and Receptors
The term “eicosanoids” includes prostaglandins (PGs),
tromboxanes (TX), leukotrienes (LTs), and hydroxyl-
eicosatetraenoic acid made by polyunsaturated 20-carbon
fatty acids (PUFA), including the most abundant and bi-
ological precursor AA [21]. The AA, a normal component
of cell membrane phospholipids, serve as substrate for
prostaglandin endoperoxide (PGH) syntases-1 and -2, also
known as cycloxygenase (COX)-1 and -2, lipoxygenase (5-,
12-, or 15) (LO), or cytochrome p450 enzymes [18].
LTs exert their biological eﬀects by activating speciﬁc
receptors belonging to the superfamily of G protein-coupled
receptors (GPCRs) [22–24] .T w or e c e p t o r sf o rL T B 4 have
been molecularly identiﬁed: BLT1 and BLT2. BLT1 is a high-
aﬃn i t yr e c e p t o rs p e c i ﬁ cf o rL T B 4, which is expressed pri-
marily in leukocytes and mediates chemotaxis [25]; BLT2 is
a pharmacologically distinct receptor, which is ubiquitously
expressed and displays low aﬃnity for LTB4 and also binds
other eicosanoids [26, 27]. The ubiquitous expression and
the broader ligand speciﬁcity suggest that BLT2 may mediate
distinct biological and pathophysiological roles from BLT1.
Receptors responding to Cys-LTs have been cloned in
1999 and termed CysLT1 and CysLT2 [22]. CysLT1 recom-
binant receptor is activated by all the native ligands, with a
rank-orderpotencyofLTD4>LTC4 >LTE4 [28,29],whereas
for CysLT2 receptor the agonist rank order potency is LTD4 =
LTC4 with LTE4 less potent [30–32]. Despite the classic view
that the activity of cysteinyl-LTs is due to the interaction with
these two speciﬁc plasma membrane receptors, alternative
pathways have been postulated, including localization of
CysLT receptors at nuclear level, cross talk with other
membrane receptors, the possibility that CysLT receptors
might exist as homo/heterodimers, and the existence of
additionalreceptorsubtypes[22].TheexpressionofBLTand
CysLT subtypes on vascular smooth muscle and endothelial
cells is highly dependent on transcriptional regulation by
pro-and antiinﬂammatory mediators [22,33](seeFigure 1).
Recent experimental evidences in vitro and in vivo
suggest that all the responses can be attributed to the
existence of additional subtypes and/or to the formation of
homo- and/or heterodimers [34, 35]. Few reports suggest
that CysLTs receptors could also be localized as levels other
than on the plasma membrane, suggesting an important and
unanticipated role for these receptors in cell signalling and
function [36]. Some observations are stimulating research
towards the potential roles of the 5-LO pathway in pro-
moting inﬂammation in cardiovascular disease, including
atherosclerosis and aortic aneurysms [37]( Table 1).
A major role for the LT pathway in vascular disease was
suggested by studies of a congenic mouse strain demon-
strating that atherosclerosis resistance is linked to a locus
on chromosome 6, in which the gene for 5-LO was mapped
subsequently [38]( Table 1).
Additional evidence comes from the identiﬁcation of
enzymes and receptors in the 5-LO pathway expressed in
human atherosclerotic plaques [39] and in subjects with
atherosclerosis as measured by an increased intima-media
thickness [40]. Moreover, variants in the FLAP encoding
gene have been associated with an increased risk in humans
[41].
Therefore, multiple lines of evidence including in vitro
studies, animal models (mice and mouse strains, rat), and
some human studies implicated LTs in the pathogenesis of
atherosclerosis,andinparticularsuggestedanimportantrole
for LTB4 and BLT receptor in atherogenic processes [8, 42,
43].
4. LTs Modiﬁers: Receptor Antagonists
In order to regulate the eﬀects of Cys-LTs pharmacologically,
two general approaches have been used with success: LTs
synthesis inhibition and LTs receptor antagonism. The LT
synthesis inhibitor blocks key steps in the biosynthetic
pathway (either 5-LO or 5-LO activating protein—FLAP) to
inhibit production of both Cys-LTs and LTB4, whereas the
LTRAs selectively block the CysLT1 receptor on target cells.
Pharmaceutical agents such as montelukast, zaﬁrlukast, and
pranlukast are well tolerated and have been approved in the
USA, Europe, and other areas for the treatment of allergic
rhinitis and bronchial asthma [4, 5].
5. LTs Modiﬁers: 5-LO SynthesisInhibition
The ﬁrst committed step in the synthesis of LTs is the
oxidation of AA by 5-LO, and the integral membrane protein
FLAP is an essential partner of 5-LO for this process [44].
FLAP was molecularly identiﬁed through a photoaﬃnity
probe and an aﬃnity gel based on MK-886, a selective
leukotriene inhibitor that has no activity against broken-
cell preparations of 5-LO [45]. Several FLAP inhibitors
showed eﬃcacy in early clinical trials in asthma but were not
developed commercially for unpublished reasons [46].
Zileuton (ZIL) is the only marketed drug with a speciﬁc
eﬀect on Cys-LTs synthesis through the inhibition of the
5-LO enzyme, administered orally four times daily (QID).
It is metabolized by the cytochrome P450 isoenzymes and
may therefore interact with other drugs metabolized by these
enzymes, such as theophylline and warfarin [47, 48]. The use
of ZIL is hampered because it needs a QID dispensing and
the monitoring of liver enzymes [49]. It is approved for the
treatment of asthma in 12-years-old patients and older ones
[48].
6. LTs Modiﬁers in the Treatment of
CardiovascularDisease
Atherosclerosis is an inﬂammatory process associated with
several pathophysiological reactions within the vascular wall
[50–52] .L T sh a v en o tb e e np e r c e i v e da sp r o m o t e r so fC V D
until recently, despite actions of LTs in the cardiovascular
system (CVS).
The connection originated from mouse genetic studies,
where a locus on chromosome 6 was identiﬁed to con-
fer almost total resistance to atherogenesis [53]; further
analysis identiﬁed 5-LO as a major gene contributing toMediators of Inﬂammation 3
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Figure 1: Leukotrienes biosynthesis scheme.
Table 1: Step of biosynthetic pathway, site of action, and blocking agents.
Step of biosynthetic pathway Site of action Blocking agent
Flap (ﬁve-lipoxygenase activating protein) Cell membrane Not developed commercially
5-LO (5-lipoxygenase) Citosol Zileuton
Citosol Via-2291
Translocation of 5-lipoxygenase Binding sites DG-031 (BAY × 1005)
Cell membrane
CysLT1 receptor Target cells
Montelukast
Zaﬁrlukast
Pranlukast
atherosclerosis susceptibility in mice [54]. 5-LO was found
to be present in human atherosclerotic aorta, coronary
and carotid arteries [55]a n dv a r i a n t5 - L Og e n o t y p e s
identiﬁed a subpopulation with increased atherosclerosis
[56]. Also studies on FLAP and LTA4 hydrolase support
involvement of LTs in human atherosclerosis [57–59]. The
importance of the link between 5-LO and atherosclerosis
has been exhaustively reviewed [59–61]. However, a recent
quantitative analysis of atherosclerotic lesions in 5-LO−/−
mice seems to argue with a role of the 5-LO pathway in
intermediate to advanced atherosclerotic lesion development
[62].
LT products of 5-LO are primarily produced by mono-
cyte macrophages in the arterial intima, foster the chemoat-
traction of monocytes, T-cells, or other types of circulating
cells within the vessel wall, increase vascular permeability, or
both through activation of LT receptors. Following are the
circumstantial and experimental evidence supporting a link
between LTs, their receptors, and atherosclerosis.
6.1. DG-031 (BAY × 1005). DG-031, formerly known as
BAY×1005,actsbybindingtheFLAPproteinandpreventing
the translocation of 5-LO from the citosol to the cell
membrane. This drug both competes for binding sites on4 Mediators of Inﬂammation
the cell membrane with 5-LO and is a functional competitive
inhibitor of FLAP. deCODE genetics has linked variants in
the gene encoding FLAP and the gene encoding leukotriene
A4 hydrolase (LTA4H) to the risk of heart attack. These
variants appear to confer increased risk of heart attack
by increasing the production of LTB4,ap o t e n td r i v e ro f
inﬂammation produced in atherosclerotic plaques.
Hakonarson et al. [63]c o n d u c t e dar a n d o m i z e d ,
placebo-controlled, crossover trial about DG-031 on 268
patients and found a signiﬁcant dose-dependent suppression
of inﬂammatory biomarkers (LTB4 and myeloperoxidase)
associatedwiththeriskofMI.Inthisstudy,patientswereﬁrst
randomized to receive 250, 500, and 750mg/daily of DG-031
or placebo for 4 weeks of treatment after a 2-week wash out
period.
6.2. VIA-2291. Recently have been announced the results of
Phase 2 trials in acute coronary syndrome (ACS) investigat-
ing VIA-2291, a selective and reversible inhibitor of 5-LO,
a key enzyme in LTs biosynthesis. The ACS Phase 2 study
of VIA-2291 was designed to establish optimal dosing and
safety data in 191 patients with ACS, who recently had a
heart attack or unstable angina. Patients were treated once
daily for 12 weeks with one of three doses of VIA-2291
or placebo. In order to further evaluate VIA-2291’s eﬀect
over a longer timeframe, a substudy of patients in the ACS
trial continued for additional 12 weeks of treatment at the
same dose followed by a 64-slice multidetector computed
tomography (MDCT) scan following up on the baseline
MDCT scan that all patients had received. The statistical
outcomes for the ACS trial were validated by an independent
academic statistics group at Montreal Heart Institute. The
ACS trial demonstrated a statistically signiﬁcant, dose-
dependent inhibition of ex vivo-stimulated LTB4 production
at 12 weeks. LTB4 production was measured at trough, just
before the next dose of VIA-2291 was taken, indicating a
sustained pharmacological eﬀect of the drug between doses.
The secondary endpoint of change from baseline in urine
LTE4,alsoshowedsigniﬁcantinhibitionatalldoselevels.The
drug was generally well tolerated in the trials. Common (>10
percent) adverse events with no clear diﬀerence between
placebo and VIA-2291 treated patients included angina,
fatigue, musculoskeletal pain, and headache. Laboratory
abnormalities included generally mild, reversible ≥ 3x upper
limit of normal liver enzymes in the low-dose VIA-2291
treated group (10 percent) and placebo (2 percent), not seen
in the higher-dose drug-treated groups, and asymptomatic
≥1.5xlipaseelevationsthatweremorecommoninVIA-2291
treated patients [44].
7. Conclusion
LTs are potent inﬂammatory mediators synthesized within
the cardiovascular system through the 5-LO pathway of
AA metabolism. CysLTs are vasoconstrictors and induce
endothelium dependent vascular response through the Cys-
LT1, and Cys-LT2 receptor subtypes. Taken together, exper-
imental and genetic studies suggest a major role of LTs in
atherosclerosis and in its ischemic complications such as
acute coronary syndromes and stroke [64].
Furthermore, the eﬀects on vascular smooth muscle cells
suggest a role in the vascular remodeling observed after
coronaric angioplasty, as well as in aortic aneurysm. Further
experimentalandclinicalstudiesareneededtodeterminethe
potential therapeutic strategies targeting the LT pathway in
cardiovascular disease [65, 66]. Recent evidences regarding
the application of LT modiﬁers greatly increased a potential
use of these drugs in cardiovascular and cerebrovascular
diseases. The exact role of LTRAs in disease management
is still evolving. Large-scale, controlled trials are needed to
determine the eﬀectiveness and the safety deriving from the
use of LTRAs in cardiovascular diseases [67].
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